EXPERIENCE WITH THE USE OF PIOGLITAZONE FOR THE PREVENTION AND TREATMENT OF EXPERIMENTAL URATE NEPHROLITHIASIS-Reference-Cited by-同舟云学术

EXPERIENCE WITH THE USE OF PIOGLITAZONE FOR THE PREVENTION AND TREATMENT OF EXPERIMENTAL URATE NEPHROLITHIASIS

Published:2017-03-03 Issue:1 Volume:21 Page:52-56
ISSN:2541-9439
Container-title:Nephrology (Saint-Petersburg)
language:
Short-container-title:Nefrologiâ (St.-Peterbg.)

Author:

Perfiliev V. Y.¹,Zverev Y. F.¹,Zharikov A. Y.¹,Lukiyanenko D. Y.¹,Lysenko I. V.¹,Atabaeva O. S.¹

Affiliation:

1. Altai State Medical University

Abstract

THE AIM. To assess the effectiveness of selective agonist of PPAR gamma receptors (Peroxisome Proliferator-Activated Receptor) pioglitazone, as a drug of prevention and treatment of experimental urate nephropathy. MATERIAL AND METHODS. The study was conducted on 37 male rats Wistar stock. For the formation of urate nephropathy in rats inhibited uricase by co-administration of uric acid and oxonium. For the prevention and treatment of experimental pathology animals received pioglitazone. On day 21 using biochemical and morphological techniques were evaluated received changes. RESULTS. In the experimental condition were observed significant decrease of urate stones in kidneys, significant decrease of uric acid in blood plasma and urine of rats, increase of the urine pH, increase of glomerular filtration rate and inhibition processes of free radical oxidation in the blood of animals. CONCLUSION. Long-term use of pioglitazone in the preventive and therapeutic modes, significantly improves the experimental urate nephrolithiasis.

Publisher

Non-profit organization Nephrology

Subject

Nephrology

Reference18 articles.

1. Kalashnikova MF. Metabolicheskii sindrom: sovremennyi vzglyad na kontseptsiyu, metody profilaktiki i lecheniya. Effektivnaya farmakoterapiya 2013; 52: 52-63 [Kalashnikova MF. Metabolicheskij sindrom: sovremennyj vzgljad na koncepciju, metody profilaktiki i lechenija. Jeffektivnaja farmakoterapija. 2013; 52: 52-63]

2. Kim Y-J, Kim C-H, Sung E-J et al. Association of nephrolithiasis with metabolic syndrome and its components. Metabolism 2013; 62 (6): 808-813

3. Antipova VN, Kazeeva MV. Kardiovaskulyarnyi risk i metabolicheskii sindrom u bol'nykh podagroi. Izv vysshikh uchebnykh zavedenii. Povolzhskii region. Med nauki 2015; 1 (33): 112-122 [Antipova VN, Kazeeva MV. Kardiovaskuljarnyj risk i metabolicheskij sindrom u bol’nyh podagroj. Izvestija vysshih uchebnyh zavedenij. Povolzhskij region. Medicinskie nauki 2015; 1 (33): 112-122]

4. Bokarev IN. Metabolicheskii sindrom. Klin med 2014; 92 (8): 71-76 [Bokarev IN. Metabolicheskij sindrom. Klinicheskaja medicina 2014; 92 (8): 71-76]

5. Barskova VG, Eliseev MS, Denisov IS i dr. Chastota metabolicheskogo sindroma i soputstvuyushchikh zabolevanii u bol'nykh podagroi. Dannye mnogotsentrovogo issledovaniya Nauch-prakt revmatol 2012; 50 (6): 15-18 [Barskova VG, Eliseev MS, Denisov IS i dr. Chastota metabolicheskogo sindroma i soputstvujushhih zabolevanij u bol'nyh podagroj. Dannye mnogocentrovogo issledovanija Nauchno-prakticheskaja revmatologija. 2012; 50 (6): 15-18]